NCT06465199 2026-04-13
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT06219174 2026-03-06
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Suspended
NCT04696029 2026-03-02
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT04301843 2026-02-03
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02679144 2026-01-21
NMTT
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07321912 2026-01-08
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Phase 2 Not yet recruiting
NCT04091022 2025-12-17
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT05717153 2025-11-04
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT06892678 2025-05-11
DFMO
Montefiore Medical Center
Phase 1/2 Recruiting